- 🔴 Insolvency / collective proceedings on file (1)
Think this is wrong? This is an automated estimate — request a human review or correction.
METAFORA BIOSYSTEMS
Simplified joint-stock company (SAS) · RC 530932672 · Active since 2011
Overview
METAFORA BIOSYSTEMS is a simplified joint-stock company (sas) registered in France, since 2011. The company operates in the scientific research & development sector. With reported revenue of 166K EUR in 2023. Its TraceComp score of 77 (B+) indicates solid fundamentals and low apparent risk. With 15 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 530932672
- Legal Form
- Simplified joint-stock company (SAS)
- Registered
- 2011-03-08
Financial Profile
Latest filed accounts: FY 2023 · most recent available in public filings
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Insolvency & Collective Proceedings
1 insolvency / collective-proceedings notice on file — most recent published 2026-03-11. A material adverse finding for counterparty and credit risk.
Insolvency notice types, titles, publication dates and official Gazette sources.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
EU Funding
EU-funded innovation. Participated in 3 EU research projects, receiving €5,752,109 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).
Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.
Patent Portfolio
Active patent holder. 3 patents · 3 active · 3 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue up 44% year-on-year
- Net loss reported in FY 2023
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.